Background/aim Screening of young competitive athletes remains a contentious issue. In 2010, a nationwide cardiac screening for all elite rugby players was introduced in England. This provided a unique opportunity to prospectively assess the feasibility and cost-effectiveness of a de novo, ECG-based cardiac screening programme. Methods Between 2010 and 2012, 1191 rugby players aged ≥14 years underwent cardiac screening with a health questionnaire, 12-lead ECG and a consultation with a cardiologist. The players with concerning findings on initial evaluation were offered on-site transthoracic echocardiogram (TTE). Athletes were referred for further investigations as deemed necessary. The overall cost of the screening programme was estimated.
INTRODUCTION
Sudden cardiac death (SCD) is one of the leading causes of death in young (≤35 years) athletes. The majority of deaths are attributed to inherited or congenital cardiac disorders, some of which can be detected during life. 1 2 A mandatory, ECG-based, preparticipation cardiac screening (PPS) programme in the Veneto region of Italy reported a reduction in the incidence of SCD in young athletes. 3 Based on these results, a number of international sporting and scientific organisations advocate cardiac screening of young competitive athletes for the prevention of such tragedies. 4 5 However, there is debate over its feasibility, relating primarily to the potentially large number of false-positive tests and associated costs. In the current era, where national health systems have limited financial resources, a large number of specialist investigations aiming to reassure athletes with an abnormal ECG are likely to be cost prohibitive. In an attempt to improve the specificity of ECG, the European Society of Cardiology (ESC) and other expert consortia have revised the original 2005 criteria relating to which ECG changes should raise suspicion of underlying heart disease. [6] [7] [8] In the UK there is no state-sponsored cardiac screening programme. In 2010, a nationwide cardiac screening for all eligible rugby players aged ≥14 years was introduced in England. This provided a unique opportunity to prospectively assess the feasibility and cost-effectiveness of an ECG-based cardiac screening programme in a real-world model. In addition, we retrospectively compared the performance of the newly proposed 'Seattle' and 'Refined' criteria with those currently recommended by the ESC. [6] [7] [8] 
METHODS Setting
Cardiac screening of elite rugby players selected to represent England has been in place since 2005. In 2010, the Rugby Football Union, Premiership Rugby and the Rugby Players Association expanded the programme offering cardiac screening to all players (aged ≥14 years) representing England or registered with the Premiership clubs and the Regional Academies. All screenings were conducted by the charitable organisation cardiac risk in the young (CRY). The screening team consisted of a screening manager, a team of accredited cardiac physiologists and a cardiology fellow. Results were reviewed by the senior author with more than 25 years of experience in sports cardiology and inherited cardiac diseases. The cardiac screening included a detailed health questionnaire, a 12-lead ECG and a consultation with a cardiologist. On-site transthoracic echocardiogram (TTE) was available for individuals with an abnormality during the initial evaluation. Athletes with high index of suspicion for heart disease were referred for further evaluation and/or regular follow-up.
Health questionnaire
The health questionnaire evaluated the presence of cardiovascular symptoms, family history of inherited cardiac disease or premature SCD (≤40 years) and drug history. In addition, ethnicity data as well as training level and duration were collected.
Twelve-lead ECG
A standard 12-lead ECG was performed during quiet respiration at rest in all athletes using a Philips Pagewriter Trim III (Philips, Bothell, Washington, USA). The ECG trace was stored electronically. The ECG findings were classified as 'Group 1' or 'training-related' and 'Group 2' or 'training-unrelated' changes. In order to assess the impact of alternative ECG criteria on screening outcomes, all ECGs were reviewed retrospectively in accordance with: (1) the ESC 2010 recommendations, 6 (2) the 'Seattle' criteria 7 and (3) the 'Refined' criteria. 8 Table 1 outlines the definitions of 'Group 2' ECG changes in our study and provides a comparison with the respective definitions of 'Group 2' changes as outlined in the ESC criteria, the 'Seattle' criteria and the 'Refined' criteria. [6] [7] [8] 
Cardiology consultation
The cardiology consultation consisted of a comprehensive review of the questionnaire and 12-lead ECG and the measurement of height, weight and brachial blood pressure. Cardiovascular physical examination was performed selectively in athletes who reported clinically relevant symptoms or prior medical history.
Transthoracic echocardiogram
Two-dimensional transthoracic echocardiogram (TTE) was performed by a British Society of Echocardiography-accredited cardiologist or a senior cardiac physiologist. A Philips iE33 or Philips CX50 machine with 3 MHz transducer was used. Standard views were obtained, and chamber and wall thickness measurements were performed as per current guidelines. Continuous-wave and pulsed-wave Doppler, as well as tissue-Doppler, images were acquired. 10 
Further evaluation and follow-up
Athletes with personal or family history, ECG or echocardiographic anomalies suggestive of underlying cardiac pathology were invited for further clinical evaluation. All further evaluations were performed after referral by the relevant player's family physician to a specialist cardiac centre via the National Health Service (NHS). Evaluations were dictated by the local protocols of the relevant specialist centre. Athletes with phenotypes outside the conventional limits but considered most likely to represent cardiac adaptation to exercise were invited for repeat cardiac evaluations on an annual or 2-yearly basis.
Cost analysis
The cost of the initial cardiac screening, including questionnaire, 12-lead ECG, consultation and on-site TTE when required, was set at £35 per athlete. This rate is based on the subsidised rate charged by CRY for young individuals in the UK who wish to be screened. The additional costs of the screening programme are funded by the charity's fundraising activities and voluntary work by participating individuals; these potential expenses were not accounted in this study. Costs resulting from referral to specialist centres and further diagnostic tests were derived from the NHS payment-by-result tariff 2012-2013 as detailed in table 2.
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Ethical approval/consent Ethical approval was granted by the National Research Ethics Service, Essex 2 Research Ethics Committee.
Statistical analysis
Data manipulation and analysis were performed using SPSS software, V.20 (Chicago, Illinois, USA). Values were expressed as mean±SD or percentages, as appropriate.
RESULTS

Health questionnaire
Between January 2010 and December 2012, 1191 male rugby players (aged 14-37 years) underwent PPS. Detailed demographics of the rugby players are reported in table 3.
A significant proportion of athletes (n=179; 15%) reported one or more symptoms in their health questionnaire, including dizziness (n=101; 8.5%), chest pain/tightness (n=71; 5.9%), syncope (n=48; 4%), palpitations (n=47; 3.9%) and shortness of breath (n=31; 2.6%). Only 18 athletes (1.5%) reported symptoms related to exertion. After consultation with the cardiologist, only six (0.5%) athletes were considered to exhibit clinically significant symptoms requiring further evaluation. Ten (0.8%) athletes reported a family history of premature SCD or an inherited cardiac disease. One athlete had a history of dilated aortic root based on previous screening. Thirty-six (3%) athletes reported a history of asthma.
Physical examination
None of the athletes exhibited elevated blood pressure of >140/ 90 mm Hg. Cardiovascular examination in a selected number of athletes did not identify any abnormalities requiring further evaluation.
12-Lead ECG
Group 1 ECG changes were detected in 691 (58%) athletes, whereas 107 (9%) athletes exhibited at least one group 2 change (figure 1). The most prevalent group 2 ECG anomaly was T-wave inversion, which was present in 42 (3.5%) athletes. T-wave inversion confined to the anterior leads was present in 12 (1%) athletes. Only four (0.3%) athletes exhibited anterior T-wave inversion extending beyond lead V2, which overlapped with arrhythmogenic right ventricular cardiomyopathy (ARVC). In 27 (2.3%) athletes, the inferior leads were involved and 3 (0.25%) athletes exhibited T-wave inversion in the lateral leads. Bundle branch block was rare (0.7%), with RBBB being the predominant pattern. Pathological Q-waves were present in only one athlete, while ST-segment depression was not identified in any athlete. Voltage criterion for axis deviation, atrial enlargement and RVH were present in 3.7%, 1.1% and 1% of athletes, respectively. A prolonged QTc (>470 ms) was seen in three (0.25%) athletes, none of whom had symptoms or relevant family history of note. One athlete exhibited pre-excitation consistent with an accessory pathway ( 
Further diagnostic evaluation and follow-up
Of the 115 athletes requiring TTE: 81 (70%) were cleared after a normal scan; 8 players (5 with minor cardiac abnormalities and 3 with absolute LVEDD of >65 mm) were referred for surveillance TTE and 26 players were referred for further comprehensive evaluation. Further diagnostic evaluation included cardiac MRI (n=13), exercise treadmill/cardiopulmonary test (n=18) and 24-hour ECG monitoring (n=20). Two athletes were diagnosed with a condition predisposing to exercise-related SCD. An athlete with the Wolf-Parkinson-White phenotype (figure 3A) was referred for an electrophysiological study and underwent radiofrequency ablation of the accessory pathway, following which he returned to competition. One athlete with T-wave inversion extending to the lateral leads (figure 3B) but normal TTE at initial screening was diagnosed with hypertrophic cardiomyopathy (HCM) during subsequent evaluation and follow-up. Another athlete with T-wave inversions in anterior and lateral leads (I, aVL, V2-V4) did not demonstrate any abnormality on extensive evaluation. He continues to compete but remains under follow-up on an annual basis. One player exhibited a small PDA with little haemodynamic significance and was asymptomatic; he continues to compete with repeat TTE every 2 years. Those with dilated LV cavity underwent surveillance TTE which did not show any significant progression on serial evaluation; their LV dimensions were deemed acceptable when indexed to body surface area, in the absence of other features suggestive of disease. The remaining players with minor abnormalities undergo annual or 2-yearly TTE. The three athletes with prolonged QTc did not demonstrate any features suggestive of long-QT syndrome. During a mean follow-up period of 52.8 ±5.5 months, none of the players who were reassured experienced any adverse cardiac events. Three players were lost to follow-up: one with family history of sudden death and two with pathological T-wave inversions.
Cost of screening programme and further investigations
Based on the subsidised fee of £35 per player charged by CRY, the cost of the initial screening for all 1191 rugby players was £41 685, including on-site TTE when required (table 2). The cost of the referrals to an NHS specialist cardiac centre for additional tests was £18 190, mounting to a total cost of £59 875 or £50 per player screened. A total of seven players were identified with an abnormality; of these, two had serious and potentially life-threatening cardiac disease (one HCM, one WPW) and another five needed long-term surveillance. Thus the cost of identifying a player with any cardiac abnormality was £8554 while the cost of identifying one player with a potentially lifethreatening condition was £29 938.
The false-positive rate for the screening programme comprised health questionnaire, ECG and consultation was 9.5%; the majority (96 of the 115 cases) comprised a false-positive ECG. The inclusion of selective on-site TTE reduced the falsepositive rate to 2.7% by clearing 81 cases that would otherwise require referral to a cardiology specialist for further evaluation. That would equate to overall savings of £21 627 (£18 per athlete screened), assuming that every individual referred to a specialist would require as a minimum a cardiology consultation and a TTE as part of their evaluation.
Evaluation of different ECG screening criteria
Using the 2010 ESC ECG criteria (table 1) would have increased the ECG false-positive rate from 8.8% to 20.1%, 12 ( †QT interval was corrected for heart rate (QTc) using Bazett's formula. AV, atrioventricular; ER, early repolarisation.
predominantly due to the inclusion of athletes outside the conservative QTc intervals (n=58 with QTc<380 ms; n=53 with QTc>440 ms) and the definition of ventricular pre-excitation by the presence of a PR interval of <120 ms, even in the absence of pre-excitation (n=23). 6 On the contrary, using the 'Seattle' criteria (table 1) would have resulted in an overall reduction of the ECG false-positive rate from 8.8% to 6.5%, 7 primarily due to differences in the definition of T-wave inversion. Finally, the 'Refined' ECG criteria would have resulted in a further reduction of the ECG false-positive rate to 4.9% due to the inclusion of ECG criteria for atrial enlargement, QRS axis deviation and right ventricular hypertrophy, when present in isolation, to normal variants (table 4) . 8 
DISCUSSION
This is the first large-scale study to report on a real-world, nationwide screening programme of elite competitive athletes from a single sporting discipline. Importantly, this study involves a cohort of athletes of extraordinary size and strength often considered likely to exhibit a higher prevalence of ECG anomalies and extremes of cardiac dimensions, posing a greater challenge in differentiating athlete's heart from quiescent cardiac disease.
Value of individual screening modalities
In our study, both athletes with potentially life-threatening cardiac abnormalities were detected on the basis of an abnormal ECG. Reassuringly, the ECG would have flagged both players for further evaluation, irrespective of the criteria used. On the contrary, of the 179 (15%) athletes who reported symptoms on the questionnaire, only 0.5% was considered significant after consultation with our cardiologists and none demonstrated any significant abnormality on further investigations or follow-up. This underscores the poor predictive value of symptoms as indicators of cardiac disease in young athletes.
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Utility of different ECG criteria
Our study demonstrated a ECG false-positive rate of 8.8% using our group's criteria that are similar to the criteria proposed by the ESC in 2010 with notable exception in the definitions of an abnormal QT interval and pre-excitation. This is reassuring given the athletic prowess and body habitus of our athletes, as it compares favourably with the false-positive rates reported in the literature. 15 It is widely accepted that the criteria recommended by the ESC for the interpretation of a young athlete's ECG require refinement in order to incorporate data that have emerged since 2010 and to accommodate for the effect of ethnicity, age, gender and sporting discipline on the athlete's ECG. [16] [17] [18] [19] [20] [21] This led to the 2013 Seattle criteria and the 2014 'Refined' criteria which on an initial assessment appear to improve specificity without compromising the sensitivity of the ECG in detecting potentially sinister cardiac disease. 8 22-26 In agreement with current literature, the adoption of the 2010 ESC criteria in our cohort would have resulted in an unacceptably high proportion (20%) of athletes requiring further evaluation with escalating costs. In contrast, the application of the 'Seattle' and the 'Refined' criteria would have reduced the falsepositive rate to 6.5% and 5%, respectively, while still identifying the two athletes with potentially life-threatening conditions.
Cost-effectiveness of cardiac screening
Literature on the cost-effectiveness of cardiac screening suggests highly variable costs ranging from $42 900 per life-year saved to $14.4 million per life saved. These results should be viewed with caution as the respective studies exhibit several limitations; using theoretical projection models rather than true costs, extrapolating results from the Italian experience to US highschool athletes and making arbitrary assumptions relating to the life years saved by identifying a potentially life-threatening condition. [27] [28] [29] In a Swiss study where the true NHS rates were used to assess the cost of screening of young athletic individuals, the authors reported costs of £108 per athlete screened and £29 000 per potentially life-threatening condition identified (three WPW, one LQTS). 30 Our study reports on a de novo nationwide screening programme of elite, professional athletes, and estimates costs using the subsidised screening fee required for our programme. The cost of £50 per player or £29 938 per condition identified would be considered within the conventional cost-effectiveness limits used in most healthcare systems. There is general consensus that ECG should be routinely used, but routine TTE is not recommended as part of the initial evaluation, as it improves only the diagnostic yield of congenital abnormalities and not of conditions predisposing to SCD in young athletes and is associated with a high cost. 8 29-32 This would have also been true for our screening programme as performing a TTE in every player would have considerably reduced the number of players screened per session and significantly affected our resources and associated costs. The addition of on-site TTE as a second-line investigation, however, reduced the athletes requiring referral for further evaluation from 9.7% to 2.9%, resulting in considerable savings. In addition, excluding a severe disease phenotype using on-site TTE offers considerable reassurance to the player, team and physician until further investigations are completed.
Limitations
The reported costs were heavily subsidised by the charitable organisation CRY. The nominal fee of £35 for an ECG, a consultation with a cardiologist and TTE would not apply to most existing clinical settings. As such they significantly underestimate the true cost of screening, being a high-quality outreachscreening programme or cardiovascular screening through NHS or the private sector. If we substitute the CRY fee of £35 for the cost of a cardiology consultation and 12-lead ECG (£210) that the NHS in England charges, then the cost would rise to £225 per athlete screened and £134 150 per condition identified. However, the aim of the study was to present a real-life, sustainable screening programme. Cardiac risk in the young is a wellestablished charity in existence since 1996. Since its inception, the screening programme has expanded and the charity currently screens in excess of 20 000 young individuals per annum with the exact screening protocol described in this study. Funds to cover the additional expenses of screening are raised through voluntary work and the charity's activities. As such, although the costs associated with screening young athletes may seem unattainable for the strained financial resources of many healthcare systems, our study provides at the very least a convincing argument for alternative funding sources that national healthcare systems should consider.
The screenings were supervised by a dedicated cardiology fellow with interest in sports cardiology and inherited cardiac conditions. Therefore, the results may not be reproducible in a team of physicians with less experience, resulting in greater false-positive rate, with impact on resources and associated costs. An expert setting, however, needs to be assured prior to embarking on a screening programme.
Finally, our study cohort was limited to men and predominantly Caucasian athletes.
CONCLUSION
Our study on a well-characterised cohort of elite professional athletes demonstrates that cardiac screening with 12-lead ECG is feasible and may result in the identification of potentially sinister conditions. The refinement of the ECG criteria, the availability of on-site echocardiography and the expert setting safeguard a relatively low false-positive rate, minimise the burden of unnecessary investigations and reduce costs. 
